The Global Radiation-Induced Myelosuppression Treatment Industry is on an upward trajectory, with projected sales totaling US$ 2.9 Billion in 2022. According to the latest insights from Future Market Insights, the market’s robust growth is attributed to a steady Compound Annual Growth Rate (CAGR) of 3.1%, positioning it to achieve an impressive valuation exceeding US$ 3.5 Billion by 2028.
This remarkable expansion is driven by several factors, notably the rapid improvement in healthcare infrastructure and the evolving reimbursement scenario. These factors have become pivotal boosters for the healthcare industry, particularly in developing regional markets.
Radiation therapy has been a significant part of cancer treatment and the consistently high success rate associated with radiotherapy is projected to further push demand for radiation-induced myelosuppression treatment worldwide.
Neutropenia is foreseen to generate maximum demand for radiation-induced myelosuppression treatment, whereas injectables are identified to hold a substantial share in the total market value, based on the route of administration of radiation-induced myelosuppression treatment. Thrombocytopenia and anemia are likely to present lucrative opportunities for radiation-induced myelosuppression treatment providers.
Request a Sample of this Report Now!
https://www.futuremarketinsights.com/reports/sample/rep-gb-8116
The report tracks key factors driving revenue growth of the market –
- Increasing prevalence of cancers
- Early diagnosis, promises improved chances of positive outcomes
- Fostering R&D funds supporting cancer research
- Strong product pipeline
- Bolstering adoption of chemo-radiotherapy in cancer treatment
Against the backdrop of patent expiry, a majority of market leaders are shifting their focus to the expansion of the product pipeline of a wide range of innovative formulations, likely to shape the radiation-induced myelosuppression treatment landscape.
- Myelo001 by Myelo Therapeutics GmbH recently received FDA approval as an orphan drug to be used in the ARS (acute radiation syndrome) treatment.
- Mylan NV and Pfizer Inc. also received FDA approvals for their recently launched biosimilars – Epogen Neupogen, and Neulasta respectively.
Patent expiry of originator biologics formulations is creating investment opportunities in biosimilar production – for the operators in the radiation-induced myelosuppression treatment landscape. As there is a considerable cost difference of around 20% between originator biologics and biosimilars, patients are inclined more towards an economical means of treatment, thereby fueling the scope of penetration of radiation-induced myelosuppression treatment in coming years.
Click Here to Request Methodology!
https://www.futuremarketinsights.com/request-report-methodology/rep-gb-8116
Backed by a majority of established players housing strong bases across North America, especially the US, the report indicates a steady growth outlook for the Global Radiation-Induced Myelosuppression Treatment Industry in the region. North America will reportedly continue to account for over 65% share in the global market value.
New product launches currently mark the top developmental strategy adopted by leading companies competing in the Global Radiation-Induced Myelosuppression Treatment Industry. A majority of key players are also identified to focus on enhancing their geographical foothold in the global radiation-induced myelosuppression treatment landscape. The report in a distinct section covers some of the key competitors operating in the radiation-induced myelosuppression treatment marketplace, emphasizing their financial as well as strategic profiles in depth.
A few of the profiled companies include Pfizer Inc., Janssen Pharmaceutical NV, Janssen Global Services, LLC (Johnson & Johnson), Amgen Inc., Mylan NV, Teva Pharmaceutical Industries Ltd., Novartis AG, and Partner Therapeutics, Inc.
In the highly consolidated competitive landscape of global radiation-induced myelosuppression treatment, the three top-ranking companies, i.e. Janssen Pharmaceutical NV, Amgen Inc., and Teva Pharmaceutical Industries Ltd. dominate in terms of market value. These players continue to hold winning revenue shares in the radiation-induced myelosuppression treatment owing to a strong global presence and a considerable number of new drug approvals. Established companies are entering strategic partnerships and collaborations with regional leaders, to achieve better penetration into regional markets.
Reach Out to Our Analyst For Your Queries
https://www.futuremarketinsights.com/ask-question/rep-gb-8116
Global Radiation-Induced Myelosuppression Treatment Industry by Category
Indication:
- Neutropenia
- Anemia
- Thrombocytopenia
Drug Class:
- Growth factors
- Erythropoietin stimulating agents
- Thrombopoietin agents
- Iron supplements
Route of Administration:
- Oral
- Injectable
Distribution Channel:
- Hospital pharmacies
- Retail pharmacies
- Online pharmacies
- Drug stores
Region
- North America
- Latin America
- Europe
- East Asia
- South Asia
- Oceania
- Middle East & Africa
